Patients with a history of stroke or intracranial hemorrhage within 6 months prior to registration are not eligible
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
No active intracranial metastases
History of stroke/intracranial hemorrhage =< 6 months prior to registration
History of stroke or intracranial hemorrhage within 6 months prior to randomization
History of stroke or intracranial hemorrhage within 6 months of first dose
Intracranial hemorrhage grade > 1 not attributable to recent neurosurgery
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Any history of symptomatic intracranial hemorrhage.
Patients should not have a stroke or intracranial hemorrhage within last 6 months
Patients will not be eligible if they have a history of intracranial hemorrhage in past 6 months
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of ischemic stroke or intracranial hemorrhage =< 180 days prior to pre-registration
History of stroke/intracranial hemorrhage =< 6 months prior to registration
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months of the first dose of study drug
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months before the first dose of study drug
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Evidence of acute intracranial / intra-tumoral hemorrhage, except for participants with stable grade 1 hemorrhage.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to randomization
Intracranial hemorrhage except for tumor associated micro hemorrhage.
History of stroke or intracranial hemorrhage within 6 months prior to study entry
History of intracranial hemorrhage (either by clinical history or neuroimaging)
History of stroke or intracranial hemorrhage within 6 months of screening
No history of intracranial hemorrhage
Relapsed/refractory MCL: History of stroke or intracranial hemorrhage within 6 months prior to signing the consent
Newly diagnosed MCL: History of stroke or intracranial hemorrhage within 6 months prior to signing the consent
Evidence of recent (less than 2 weeks) intracranial hemorrhage.
Have evidence of significant (ie, symptomatic) intracranial hemorrhage.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrolment
History of stroke or intracranial hemorrhage within 3 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to signing the consent.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months before randomization.
History of stroke or intracranial hemorrhage within 6 months before randomization.
history of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or clinically significant intracranial hemorrhage within 6 months before first dose of study drug.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
No stroke or intracranial hemorrhage within the last 6 months
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Patient has history of stroke or intracranial hemorrhage =< 6 months from starting study drugs
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to study entry
Active intracranial hemorrhage
History of stroke or intracranial hemorrhage within 6 months prior to the first dose of ibrutinib
History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
History of stroke or intracranial hemorrhage within 12 months prior to enrollment.
Subjects with a history of stroke or intracranial hemorrhage within 6 months prior to enrollment are not eligible
History of stroke or intracranial hemorrhage within 6 months prior to randomization
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to random assignment
History of Grade 2 (CTCAE v4) or greater acute intracranial hemorrhage.
History of stroke or intracranial hemorrhage within 6 months prior to randomization; or clinically significant cardiovascular disease
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months of screening would be exclusion for ibrutinib therapy but idelalisib would be an option
History of stroke or intracranial hemorrhage within 6 months prior to registration
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Patients with a history of known stroke or intracranial hemorrhage within 6 months prior to study treatment are excluded
History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Patients with a history of intracranial hemorrhage are not eligible.
History of stroke or intracranial hemorrhage =< 6 months prior to registration
History of stroke or intracranial hemorrhage within 6 months prior to treatment
Evidence of significant intracranial hemorrhage
History of stroke or intracranial hemorrhage within 6 months of enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
Diagnosis of intracranial hemorrhage within the past 3 months, including intratumoral hemorrhage into brain metastases from a systemic cancer
Any history of significant hemorrhage (requiring hospitalization or transfusion) within the last 6 months (excluding hemorrhage during operative procedure)
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): History of stroke or intracranial hemorrhage within 6 months prior to screening
Patients must not have evidence of significant intracranial hemorrhage
History of stroke or intracranial hemorrhage within 6 months prior to enrollment
No hemorrhage after treatment.
History of stroke or intracranial hemorrhage within 6 months of first dose